Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …

Although the genetic causes for several rare, familial forms of Alzheimer's disease (AD) have
been identified, the etiology of the sporadic form of AD remains unclear. Here, we report a …

Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Background Based on amyloid cascade and tau hypotheses, protein biomarkers of different
Aβ and tau species in cerebrospinal fluid (CSF) and blood/plasma/serum have been …

Alzheimer's disease (AD) affects half the US population over the age of 85 and is universally
fatal following an average course of 10 years of progressive cognitive disability. Genetic and …

Most forms of Alzheimer's disease (AD) are sporadic (sAD) or inherited in a non-Mendelian
fashion, and less than 1% of cases are autosomal-dominant. Forms of sAD do not exhibit …

Alzheimer's disease (AD) is characterized by an early, asymptomatic phase (AsymAD) in
which individuals exhibit amyloid-beta (Aβ) plaque accumulation in the absence of clinically …

Introduction We performed a comprehensive quantitative proteomics study on human
hippocampus tissue involving all Braak stages to assess changes in protein abundance …

Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

Alzheimer disease (AD) is a neurodegenerative disorder characterized pathologically by the
presence of neurofibrillary tangles and amyloid beta (Aβ) plaques in the brain. The disease …